安全剂量和癌症治疗评价

Emad Y Moawad
{"title":"安全剂量和癌症治疗评价","authors":"Emad Y Moawad","doi":"10.13189/COR.2013.010102","DOIUrl":null,"url":null,"abstract":"The aim of this research is to check the efficacy of radiotherapy after execution that helps in preserving patients' rights against the randomized dose that settled statistically and assessed in standard models ignoring patient-specific factors. Based on studying a dose-response relationship, a mathematical model is presented describes the initial tumor energy (E0Tumor) prior therapy after treatment execution -even if it was not predetermined- by monitoring the tumor response along the treatment phases and compared to the applied dose energy (E0Dose). Our model allows mechanic risk predictions to be made at high radiotherapeutic doses as well as at low doses, besides to the second cancer risk prevention. Thus, the administered dose errors could be determined and consequently preserving patients' rights to evaluate the cancer treatment through the provided mathematical model. Reasons of tumor regrowth are either underestimation or overestimation of the administered dose; the safe dose of the successful treatment occurs only in the case of: E0Dose = E0Tumor, where tumor regrowth energy in such a case would be vanished. Dose assessment by ignoring patient-specific factors and using standard models is responsible for wide range of doses that lead to tumor regrowth and second cancer risks. Current approach suggests settling down a new protocol for the proper ranges of radionuclide doses based on a personalized staging system.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"31 1","pages":"6-11"},"PeriodicalIF":0.0000,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"15","resultStr":"{\"title\":\"Safe Doses and Cancer Treatment Evaluation\",\"authors\":\"Emad Y Moawad\",\"doi\":\"10.13189/COR.2013.010102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of this research is to check the efficacy of radiotherapy after execution that helps in preserving patients' rights against the randomized dose that settled statistically and assessed in standard models ignoring patient-specific factors. Based on studying a dose-response relationship, a mathematical model is presented describes the initial tumor energy (E0Tumor) prior therapy after treatment execution -even if it was not predetermined- by monitoring the tumor response along the treatment phases and compared to the applied dose energy (E0Dose). Our model allows mechanic risk predictions to be made at high radiotherapeutic doses as well as at low doses, besides to the second cancer risk prevention. Thus, the administered dose errors could be determined and consequently preserving patients' rights to evaluate the cancer treatment through the provided mathematical model. Reasons of tumor regrowth are either underestimation or overestimation of the administered dose; the safe dose of the successful treatment occurs only in the case of: E0Dose = E0Tumor, where tumor regrowth energy in such a case would be vanished. Dose assessment by ignoring patient-specific factors and using standard models is responsible for wide range of doses that lead to tumor regrowth and second cancer risks. Current approach suggests settling down a new protocol for the proper ranges of radionuclide doses based on a personalized staging system.\",\"PeriodicalId\":15189,\"journal\":{\"name\":\"Journal of Cancer Research and Therapeutic Oncology\",\"volume\":\"31 1\",\"pages\":\"6-11\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"15\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Therapeutic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.13189/COR.2013.010102\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Therapeutic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13189/COR.2013.010102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

摘要

本研究的目的是检查放射治疗执行后的疗效,这有助于保护患者的权利,使其免受随机剂量的影响,这些随机剂量在标准模型中统计和评估,忽略了患者的具体因素。在研究剂量-反应关系的基础上,提出了一个数学模型,通过监测肿瘤在治疗阶段的反应并将其与应用剂量能(E0Dose)进行比较,来描述治疗前治疗后的初始肿瘤能量(E0Tumor),即使它不是预先确定的。我们的模型允许在高剂量和低剂量下进行机械风险预测,以及第二癌症风险预防。因此,可以确定给药剂量误差,从而通过所提供的数学模型保护患者评价癌症治疗的权利。肿瘤再生的原因是低估或高估了给药剂量;成功治疗的安全剂量只有在:E0Dose = E0Tumor的情况下才会出现,在这种情况下,肿瘤再生能量会消失。通过忽略患者特异性因素和使用标准模型进行剂量评估是导致肿瘤再生和二次癌症风险的大范围剂量的原因。目前的方法建议在个性化分期系统的基础上为放射性核素剂量的适当范围制定一个新的方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Safe Doses and Cancer Treatment Evaluation
The aim of this research is to check the efficacy of radiotherapy after execution that helps in preserving patients' rights against the randomized dose that settled statistically and assessed in standard models ignoring patient-specific factors. Based on studying a dose-response relationship, a mathematical model is presented describes the initial tumor energy (E0Tumor) prior therapy after treatment execution -even if it was not predetermined- by monitoring the tumor response along the treatment phases and compared to the applied dose energy (E0Dose). Our model allows mechanic risk predictions to be made at high radiotherapeutic doses as well as at low doses, besides to the second cancer risk prevention. Thus, the administered dose errors could be determined and consequently preserving patients' rights to evaluate the cancer treatment through the provided mathematical model. Reasons of tumor regrowth are either underestimation or overestimation of the administered dose; the safe dose of the successful treatment occurs only in the case of: E0Dose = E0Tumor, where tumor regrowth energy in such a case would be vanished. Dose assessment by ignoring patient-specific factors and using standard models is responsible for wide range of doses that lead to tumor regrowth and second cancer risks. Current approach suggests settling down a new protocol for the proper ranges of radionuclide doses based on a personalized staging system.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Construction and Analysis of Adverse Reaction Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Radiotherapy and Chemotherapy Based on Image Detection To Assess the Efficacy Outcomes of Patients Undergoing Androgen Deprivation Therapy in a Tertiary Care Hospital: A Retrospective Study Translationally Controlled Tumor Protein: A Key Target to Abrogate DNA Repair and Therapeutic Resistance in Cancer Ribociclib Improves Clinical Outcomes in Breast Cancer Brain Metastases: A Case Report Osseous Metastases of Renal Epithelioid Angiomyolipoma with Dramatic Response Through mTOR Inhibitor Therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1